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Background: The importance of significant (≥130 milliseconds [ms]) intraventricular conduction 
delay (IVCD), especially with left bundle branch block (LBBB) morphology, in patients with heart 
failure and reduced ejection fraction (HFrEF) is well recognized. However, less is known about the 
prevalence of other types of IVCD/BBB in HFrEF and little about the incidence of new IVCD/BBB 
and its relationship to outcomes in HFrEF. We addressed these questions in the PARADIGM-HF 
and ATMOSPHERE trials.  
Methods: Incidence rates and risks of the primary composite outcome of cardiovascular (CV) death 
or HF hospitalization and all-cause mortality were estimated by use of Cox regression according to 
baseline QRS duration and morphology in 11,861 patients without an intracardiac device. The 
incidence of QRS-widening during follow-up was calculated in patients (n=7,888) with baseline 
QRS<130 ms, along with outcomes related to QRS-widening and predictors of QRS-widening. 
Results: At baseline, 1,789 (15%) patients had LBBB, 524 (4%) RBBB, 454 (4%) non-specific 
IVCD, 2588 (22%), “mildly abnormal” QRS (110-129 ms) and 6506 (55%) QRS <110 ms. During 
a median follow-up of 2.5 years, the risk of the primary composite endpoint was higher among 
those with a wide QRS, irrespective of morphology: hazard ratios (95% CI) LBBB 1.36 (1.23, 
1.50), RBBB 1.54 (1.31, 1.79), nonspecific IVCD 1.65 (1.40, 1.94) and QRS 110-129 ms 1.35 
(95% CI 1.23, 1.47), compared with QRS duration <110 ms. During a median follow-up of 2.7 
years, 1234 (16%) patients developed new-onset QRS-widening ≥130 ms (6.1 per 100 patient-
years); incident LBBB occurred in 495 (6.3%) patients (2.4 per 100 patient-years). QRS 110-129 
ms, lower LVEF and heart rate, older age and longer-duration HF were independent predictors of 
incident QRS-widening. New-onset QRS-widening occurred at a rate of 14.1 per 100 patient-years 
in patients with baseline QRS 110-129 ms (incident LBBB 5.9 per 100 patient-years). Incident 
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LBBB was associated with a higher risk of the primary outcome and all-cause mortality: adjusted 
HRs 1.42 (1.12, 1.82) and 1.42 (1.11, 1.82), respectively.  
Conclusion: In patients with HFrEF, a wide QRS was associated with worse clinical outcomes 
irrespective of morphology. The annual incidence of new-onset LBBB, a potential indication for 
cardiac resynchronization therapy, was around 2.5%, and was associated with a higher risk of 
adverse outcomes, highlighting the importance of repeat ECG review in patients with HFrEF. 
 
Keywords: heart failure, left bundle branch block, prognosis, cardiac resynchronization therapy, 
electrocardiography 
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Intra-ventricular conduction delay (IVCD), particularly with a left bundle branch block (LBBB) 
morphology, results in a dyssynchronous electrical activation sequence of the heart.1 LBBB is 
known to be associated with worse outcomes in patients with heart failure and reduced ejection 
fraction (HFrEF), and cardiac resynchronization therapy (CRT) reduces the risk of worsening heart-
failure and improves survival in such patients with a QRS duration ≥130 milliseconds (ms).2-7 Less 
is known about the prevalence and prognostic significance of right bundle branch block (RBBB) 
and non-specific IVCD in HFrEF. More importantly, very little is known about the incidence and 
clinical consequences of new-onset QRS widening in patients with HFrEF.8, 9 This information is 
important as a new diagnosis of IVCD may be of prognostic importance and may identify an 
indication for CRT. 
In the present study we examined the prognostic importance of prevalent and incident QRS 
widening to a duration of ≥130 ms using data from two HFrEF trials which included a broad 
spectrum of ambulatory patients receiving contemporary therapy. The trials had nearly identical 





The design, baseline characteristics and primary results of the Prospective comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) 
and the Aliskiren Trial to Minimize OutcomeS in Patients with HEart FailuRE Trial (ATMOSPHERE) 
are published.10-14 Both trials were approved by the ethics committee at each study center. All patients 
provided written informed consent. 
 
Study Patients: For the present study we included patients without a device (pacemaker, CRT or ICD) 
and a baseline QRS duration between 60 and 240 ms (Figure 1). For analyses of incident IVCD, we 
excluded all patients with QRS≥130 ms at baseline and identified those who developed QRS-widening 
(QRS ≥130 ms) at annual follow-up ECGs and subsequently grouped these patients according to QRS 
morphology: LBBB, RBBB or non-specific IVCD (ns IVCD) with the hierarchy of LBBB>RBBB>ns 
IVCD if several different morphologies were reported.  
 
The inclusion criteria for PARADIGM-HF and ATMOSPHERE were similar and included: New York 
Heart Association (NYHA) functional class II-IV status, left ventricular ejection fraction (LVEF) ≤35% 
(initially ≤40% for PARADIGM-HF but changed to ≤35% by amendment), and a plasma B-type 
natriuretic peptide (BNP) ≥150 pg/mL or NT-proBNP ≥600 pg/mL). In both trials, patients who had 
been hospitalized for heart failure within the preceding 12 months could be enrolled with a lower 
natriuretic peptide concentration (BNP ≥100pg/ml or NT-proBNP ≥400pg/ml). Plasma NT-proBNP 
was measured in a core laboratory with the Roche Elecsys proBNP assay (Roche Diagnostics GmbH, 
Mannheim, Germany), with a coefficient of variation <2.5% at all levels tested.  
Patients were required to be taking an angiotensin converting enzyme (ACE) inhibitor or angiotensin 
receptor blocker (ARB) at a dose equivalent to enalapril 10 mg daily for at least 4 weeks before 
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screening, along with a stable dose of a beta-blocker (unless contraindicated or not tolerated) and a 
mineralocorticoid receptor antagonist, if indicated.  The exclusion criteria included history of 
intolerance of an ACE inhibitor or ARB, symptomatic hypotension (or a systolic blood pressure <100 
mmHg at screening/<95 mmHg at randomization), an estimated glomerular filtration rate (eGFR) <30 
ml/min/1.73 m2 (<40 ml/min/1.73 m2 for ATMOSPHERE) , a serum potassium concentration >5.2 
mmol/l at screening (>5.4 mmol/l at randomization) (<5.0 mmol/l and <5.2 mmol/l, respectively in 
ATMOSPHERE) or a history of angioedema. 
Study Procedures: In both PARADIGM-HF and ATMOSPHERE, patients first received enalapril (5 
or)10 mg twice daily (single-blind) 15 and then sacubitril/valsartan (single-blind) for an additional 4 to 6 
weeks in PARADIGM-HF and aliskiren plus enalapril in ATMOSPHERE. In PARADIGM-HF 
Patients tolerating both drugs at target doses were randomly assigned to enalapril 10 mg twice daily or 
sacubitril/valsartan 200 mg twice daily, and in ATMOSPHERE, patients who tolerated both drugs were 
randomized in a 1:1:1 ratio to receive: i) combination of 5 or 10 mg enalapril twice daily and aliskiren 
150 mg once daily (combination group); ii) aliskiren 150 mg once daily; iii) enalapril 5 or 10 mg twice 
daily.  
Categorization of patients according to baseline ECG findings: The case report form in each study 
asked investigators to report QRS duration (in milliseconds, ms) and there was an additional question 
about QRS morphology (specifically whether there was RBBB or LBBB). The information collected 
was used to categorize patients by baseline QRS duration: QRS <110 ms (normal), QRS 110-129 ms 
(mildly abnormal) and ≥130 ms (prolonged). Individuals with QRS ≥130 ms were additionally 
categorized by QRS morphology (i.e. LBBB, RBBB, non-specific IVCD subcategories). This resulted 
in the following 5 groups overall - 1) normal QRS duration: <110 ms (irrespective of reported QRS 
morphology), 2) mildly abnormal IVCD: QRS duration 110-129 ms (irrespective of reported QRS 
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morphology 3) LBBB: QRS ≥130 ms + LBBB morphology, 4) RBBB: QRS ≥130 ms + RBBB 
morphology, and 5) ns IVCD: QRS ≥130 ms without either LBBB or RBBB reported. 
Outcomes: In the present manuscript we focused on the primary endpoint of both trials which was the 
first occurrence of cardiovascular death or HF hospitalization, as well as each of the components 
separately. We also report death from any cause, which was a secondary endpoint in PARADIGM-HF 
and a pre-specified exploratory outcome in ATMOSPHERE, as well as the two major modes of 
cardiovascular death i.e. death due to worsening HF (“pump failure”) and sudden cardiac death. All 
suspected HF hospitalizations and deaths in each trial were adjudicated by the same endpoint 
committee. 
Statistical Analysis: Baseline characteristics are presented as means with standard deviations for 
continuous variables and frequencies and percentages for categorical variables. Event rates are 
reported per 100 patient years of follow-up according to QRS duration and for those with QRS 
duration ≥130 ms additionally according to QRS morphology. Cox proportional hazard models 
were applied to calculate hazard ratios (HR) and cumulative event curves according to QRS 
morphology with patients with no intraventricular conduction delay as reference. The adjusted Cox 
regression models included information on age, sex, race (Caucasian vs. all other), geographical 
region, study drug, NYHA class, left ventricular ejection fraction, heart rate, systolic blood 
pressure, body mass index, estimated glomerular filtration rate (eGFR), HF duration, ischaemic 
etiology, history of recent HF hospitalization and history of myocardial infarction. Log (-
log(survival)) curves were used to evaluate the proportional hazards assumption.  The assumption 
of linearity of continuous variables (age) was tested by including a variable of age squared. These 
were found to be valid unless otherwise specified. QRS duration at baseline as a continuous 
variable adjusted for other prognostic variables, is shown modelled as a restricted cubic spline 
(QRS duration 100 ms is the reference value). Predictors of new-onset QRS-widening were 
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analyzed in a logistic regression model with similar adjustments as the Cox regression model. All p 
values are two-sided, and a p value of <0.05 was considered significant. Analyses were performed 





Of the overall 11,861 patients in the analysis, 6506 participants (55%) had a normal QRS duration 
(<110 ms) and 2588 (22%) had a mildly abnormal QRS (110-129 ms). The remaining 2767 patients 
(23%) had an abnormally wide QRS (≥130 ms). Among these individuals, 1,789 (15% overall/65% 
of participants with QRS ≥130 ms) had LBBB, 524 (4%/19%) RBBB, and 454 (4%/16%) ns IVCD. 
The median (Q1, Q3) follow-up was 30 (20, 40) months. 
Baseline Characteristics: Patients with wide QRS (≥130 ms) were, in general, older (65 years vs. 
63 and 62 years for QRS 110-129 ms and QRS<110 ms, respectively), had a slightly lower systolic 
blood pressure (122 mmHg vs 123 mmHg and 124 mmHg), worse kidney function (median eGFR 
69 vs. 71 and 72 ml/min/1.73 m2 ), and longer duration of HF (>5 years in 32% vs. 29% and 21%) 
irrespective of morphology (Table 1).  
Patients with LBBB were more likely to be women (30%) compared to RBBB (13%) or ns IVCD 
(20%) and older (66 years vs 65 vs 64 years). Patients with LBBB were less likely to have an 
ischaemic aetiology (49% vs. 64% vs 63%, respectively). NT-proBNP was highest, and LVEF 
lowest, in patients with the widest QRS or LBBB. Conversely, atrial fibrillation was less common 
in patients with the widest QRS or LBBB. 
Outcomes according to baseline QRS duration and morphology: The primary composite outcome 
of HF hospitalization or cardiovascular death occurred in 1543 (24%) of patients with QRS<110 ms 
(reference), as compared to 826 (32%) patients with mildly abnormal QRS (110-129 ms),  937 
(34%) patients with any QRS ≥130 ms, 168 (37%) patients with ns IVCD, 187 (35%) patients with 
RBBB, and 582 (33%) patients with LBBB (Table 2, Figure 2). In adjusted Cox regression 
analyses, this corresponded to significantly increased risk for those with QRS 110-129 ms (HR 
1.35; 95% CI 1.23, 1.47), any QRS ≥130 ms (HR 1.44; 95% CI 1.32, 1.57), ns IVCD (HR 1.65; 
95% CI 1.40, 1.94), RBBB (HR 1.54; 95% CI 1.31, 1.79) and LBBB (HR 1.36; 95% CI 1.23, 1.50).  
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All-cause mortality occurred in 19% of patients with QRS<110 ms as compared to 26% of those 
with QRS 110-129 ms, 27% of patients with any QRS ≥130 ms, 28% of patients with ns IVCD and 
27% of patients with RBBB and 26% with LBBB. The risks in patients with a wider QRS remained 
significantly higher in adjusted analyses, using QRS<110 ms as the reference group (Table 2).  
When the two principal modes of death were examined, wide QRS was associated with a higher 
risk of both pump failure and sudden cardiac death. The increase in risk was numerically larger for 
pump failure death than for sudden death. 
 
Incidence and predictors of QRS widening and subsequent outcomes: Among 7,888 patients 
without any type of intracardiac device, and ECG with QRS duration <130 ms at baseline, 1234 
(16%) developed QRS widening to ≥130 ms detected during follow-up visits, of which 495 (6.3% 
overall, 40% of patients developing QRS widening to ≥130 ms), had LBBB morphology (Table 3, 
Figure 3). These numbers corresponded to event rates of 6,1 and 2.4 per 100 patient-years, 
respectively. In a multivariable analysis, the following were independently significant predictors of 
incident QRS widening to ≥130 ms: QRS 110-129 ms vs. <110 ms (OR 4.55 [3.98-5.19]), age per 5 
year increase (OR 1.06 [1.03-1.10]), HF duration, 1-5 years vs. <1 year (OR 1.23 [1.05-1.44]), >5 
years vs. <1 year (OR 1.29 [1.08-1.54]), LVEF per 1% decrease (OR 1.03 [1.02-1.05]), heart rate 
(per 5 bpm decrease) (OR 1.06 [1.02-1.09]), prior stroke (OR 0.77 [0.59-1.00]), see Table 5. 
Patients with incident QRS ≥130 ms had subsequently higher event rates of the primary composite 
outcome (13.9 vs 7.4 per 100 py) and all-cause mortality (13.0 vs. 4.4 per 100 py), respectively. In 
adjusted Cox regression analyses this yielded HRs of 1.49 (95% CI 1.25, 1.76) for the primary 
outcome and 1.69 (95% CI 1.43, 2.00) for all-cause mortality. A similar pattern was seen when 
restricting the comparison to new-onset LBBB vs no LBBB (Table 6). Modes of death (i.e. pump 







There are two principal findings in this study.  
First is the clear demonstration that each of RBBB and ns IVCD, which together accounted for 
about a third of patients with QRS duration ≥130 ms, were predictive of a higher risk of both 
cardiovascular death or heart failure hospitalisation and all-cause mortality, and remained so after 
adjustment for other predictors of worse outcomes, including natriuretic peptides. Indeed, the 
adjusted increments in risk were at least as high in patients with each of these two ECG findings as 
in patients with LBBB at baseline. Previous studies did not distinguish between these ECG patterns 
and/or did not have sufficient numbers patients or events to demonstrate the associations with worse 
non-fatal as well as fatal outcomes.2, 7, 16-19 Additionally, limited adjustment was possible in prior 
series, especially for natriuretic peptide level, the most powerful prognosticator of all.  
Second, in the present study, even patients with a “mildly abnormal”  QRS (110-129 ms) had a 
substantially elevated risk, an important finding given that there were almost as many individuals in 
this category (22% of overall participants) as there were individuals with QRS duration ≥130 ms 
(23% of participants).  
Collectively these findings, especially the latter, stand in stark contrast to the evidence that CRT is 
most clearly beneficial in HFrEF patients with a QRS duration ≥130 ms and a LBBB configuration 
(a Class I Level A recommendation in guidelines) and may even be harmful in individuals with a 
QRS duration <130 ms.20 Possibly relevant here is the more frequent finding of an ischaemic 
aetiology and prior myocardial infarction among patients with RBBB and ns IVCD, compared to 
patients with LBBB. Therefore, patients with RBBB and ns IVCD may have greater scar burden 
and, accordingly, less response to CRT.21  
Whatever the doubts about the value of CRT in patients with non-LBBB morphology, it is clear 
these patients are at high risk and merit intervention to reduce this risk.  Whether RBBB (and ns 
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IVCD) is merely a marker of severity of heart muscle disease or whether some other, targeted, 
intervention, in addition to optimal pharmacological treatment, might be beneficial in these patients 
is unknown. His bundle pacing might be such an approach, although this needs to be tested in 
appropriately designed prospective clinical trials. In patients with RBBB, right ventricular septal 
pacing can shorten QRS duration and this pacing modality achieved electrical resynchronization 
and improved left ventricular ejection fraction and heart failure symptoms in a study of patients 
with HFrEF and isolated RBBB.22, 23,24  
Patients with ns IVCD are a potentially greater management problem, given the much larger 
number of such individuals. While there is no indication for CRT in these individuals per se, 
biventricular pacing/CRT provided a significant benefit over right ventricular pacing in an 
important clinical trial in patients with reduced left ventricular ejection fraction (≤50%) and atrio-
ventricular block requiring permanent pacing.24 A further and novel finding of the present study is 
about the incidence of new QRS widening, along with the predictors and consequences of this. We 
found that 16% of patients developed new-onset QRS-widening to ≥130 ms over a median follow-
up of 2.7 years (6.1 per 100 patient-years). Incident LBBB occurred in 6.3% of patients (2.4 per 100 
patient-years). New-onset QRS-widening, irrespective of QRS morphology, was associated with a 
much higher subsequent rate of fatal and non-fatal outcomes. There were several independent 
predictors of new-onset QRS-widening to ≥130 ms of which the strongest was a QRS duration of 
110-129 ms, with new QRS-widening occurring at more than twice the overall rate (14.1 per 100 
patient-years), which was also the case for incident LBBB (5.9 per 100 patient-years) in individuals 
with a baseline QRS duration of 110-129 ms.   
 
We know of only one other moderately large study reporting the incidence of LBBB in patients 
HFrEF. Investigators in Hull, UK, described a cohort of 1418 newly referred outpatients with 
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HFrEF.28 Among the 473 patients without a pacemaker or baseline LBBB who had a 12 lead ECG 
at one year, 49 were found to have new LBBB (approximately 10%)., This is clearly a considerably 
higher rate than in our study (2.4% per year). However, there are several explanations for this. Most 
importantly, in the prior report from Hull, BBB was defined as a QRS duration of ≥120 ms, as was 
conventional at the time and, secondly, the Hull patients were considerably older (mean 70.5 years 
versus 62.4 years) and more were in NYHA functional class III or IV (all predictors of BBB). There 
is also the possibility that the estimate of incidence of LBBB in the Hull study is less precise, given 
that it was based on 49 cases (compared with 495 in the present study). In another small Israeli 
single-center study, 178 patients with HFrEF were followed-up for a median of 30 months, and 
incident LBBB was identified in 14 patients (7.9%).29 This is closer to our estimate, of an incidence 
of 6.3% over a median of 30 months.  Consequently, we believe that it is reasonable assumption 
that our report gives the most robust estimate of clinically relevant incident LBBB in ambulatory 
HFrEF patients with generally mild symptoms. The clinical relevance is that QRS widening to ≥130 
ms with a LBBB pattern is a potential indication for CRT implantation. Clearly, the question 
begged by our findings is whether an annual 12 lead ECG recording should be made in patients 
with HFrEF who have a mildly abnormal QRS width.   
These findings have several important limitations. The analyses reported were not planned 
prospectively. QRS duration and morphology were investigator reported and it is likely that some 
patients might have been misclassified. The trial inclusion and exclusion criteria limit the 
generalizability of our findings and the duration of follow-up was limited. ECGs were only 
recorded at yearly intervals and, given the association of QRS widening with a greater risk of death, 
it is possible that more frequent ECG recording, and longer follow-up might have identified a 
higher incidence of LBBB and evidence of QRS widening. 
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In conclusion, even a “mildly abnormal” QRS duration (110-129 ms) identifies HFrEF patients at 
high risk. A significant proportion will progress to QRS duration ≥130 ms with a LBBB 
configuration and an indication for CRT. Advanced heart failure therapies may be considered in 
patients of this type with other QRS morphologies.  
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Table 1: Baseline characteristics according to QRS duration and morphology (in those with QRS≥130ms) 
 
According to QRS duration According to morphology in pts with QRS ≥130 ms 
<110 ms  110-129 ms  ≥130 ms    p-
value 
ns IVCD RBBB   LBBB  p-
value 
No. patients 6,506 2,588 1,226  454 524 1789  
Age (years) 62.2 (12.0) 63.0 (11.5) 65.2 (11.3) <0.001 63.9 (12.4) 65.4 (11.3) 65.5 (11.0) 0.026 
Female sex 1649 (25%) 446 (17%) 697 (25%) <0.001 89 (20%) 69 (13%) 539 (30%) <0.001 
Region 
  North America 
  Latin America 
  Western Europe 
  Central Europe 






































Systolic BP (mmHg) 124 (17) 123 (17) 122 (17) <0.001 122 (16) 122 (17) 123 (17) 0.45 
Heart rate (bpm) 74 (13) 72 (12) 71 (12) <0.001 71 (12) 71 (12) 71 (11) 0.66 
BMI (kg/m2) 28 (6) 28 (5) 27 (5) 0.065 27 (5) 28 (5) 27 (5) 0.66 
eGFR (mL/min/1.73 m2) 72 (59, 86) 71 (59, 84) 69 (56, 82) <0.001 70 (57, 84) 67 (56, 81) 69 (56, 82) 0.23 
Chronic kidney disease* 1700 (26%) 690 (27%) 856 (31%) <0.001 130 (29%) 165 (32%) 561 (31%) 0.51 
Ischaemic HF aetiology 3750 (58%) 1487 (58%) 1503 (54%) 0.0095 283 (63%) 335 (64%) 882 (49%) <0.001 
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Time since diagnosis of HF 
  <1 year 
  1-5 years 









































KCCQ CSS 79 (61, 92) 79 (63, 92) 81 (64, 92) 0.033 82 (66, 92) 81 (64, 93) 80 (64, 92) 0.72 
NYHA Class 
  I 
  II 
  III 
































Hypertension 4470 (69%) 1783 (69%) 1762 (64%) <0.001 283 (62%) 327 (62%) 1152 (64%) 0.57 
Diabetes 2050 (32%) 787 (30%) 827 (30%) 0.25 135 (30%) 184 (35%) 508 (28%) 0.012 
Atrial fibrillation (history) 2425 (37%) 826 (32%) 814 (29%) <0.001 148 (33%) 190 (36%) 476 (26%) <0.001 
Atrial fibrillation (ECG) 2004 (31%) 609 (24%) 524 (19%) <0.001 95 (21%) 135 (26% 294 (16%) <0.001 
Prior HF hospitalization 3174 (49%) 1268 (49%) 1270 (46%) 0.025 201 (44%) 248 (47%) 821 (46%) 0.63 
Prior myocardial Infarction 2500 (38%) 1085 (42%) 1081 (39%) 0.0082 225 (50%) 257 (49%) 599 (34%) <0.001 
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Prior stroke 477 (7%) 216 (8%) 199 (7%) 0.19 31 (7%) 47 (9%) 121 (7%) 0.22 
Beta blockers 6013 (92%) 2381 (92%) 2498 (90%) 0.0024 407 (90%) 471 (90%) 1620 (91%) 0.78 
MRAs 2968 (46%) 1217 (47%) 1284 (46%) 0.45 210 (46%) 235 (45%) 839 (47%) 0.71 
Diuretics 5068 (78%) 2092 (81%) 2244 (81%) 0.002 369 (81%) 435 (83%) 1440 (81%) 0.43 
Digoxin 2116 (33%) 772 (30%) 866 (31%) 0.040 137 (30%) 163 (31%) 566 (32%) 0.83 
ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; HF = heart failure, ARB = angiotensin receptor blocker; BMI = body mass index; Chronic 
kidney disease = eGFR<60 ml/min/1.73m2 eGFR = estimated glomerular filtration rate; HF = Heart Failure; ICD = implantable cardioverter-defibrillator; LV = left 
ventricular; LVEF = left ventricular ejection fraction; MLHF = Minnesota Living with Heart Failure questionnaire; MRA = mineralocorticoid-receptor antagonist; 
























(95% CI) (95% CI) 
Primary composite       
Normal QRS duration (<110 ms) 1543/6506 9.6 1.00 (Ref)  1.00 (Ref)  
QRS 110-129 ms 826/2588 13.6 1.42 (1.30-1.54) <0.001 1.35 (1.23-1.47)  
QRS ≥130 ms 937/2767 14.7 1.53 (1.41-1.66) <0.001 1.44 (1.32-1.57) <0.001 
  QRS ≥130 ms + nsIVCD  168/454 16.9 1.75 (1.49-2.05) <0.001 1.65 (1.40-1.94) <0.001 
  QRS ≥130 ms + RBBB  187/524 16.0 1.66 (1.42-1.93) <0.001 1.54 (1.31-1.79) <0.001 
  QRS ≥130 ms + LBBB 582/1789 13.9 1.44 (1.31-1.59) <0.001 1.36 (1.23-1.50) <0.001 
       
HF hospitalization       
Normal QRS duration (<110 ms) 786/6506 4.9 1.00 (Ref) <0.001 1.00 (Ref) <0.001 
QRS 110-129 ms 441/2588 7.3 1.48 (1.32-1.66) <0.001 1.40 (1.24-1.58) <0.001 
QRS ≥130 ms 520/2767 8.2 1.66 (1.48-1.85) <0.001 1.56 (1.39-1.75) <0.001 
  QRS ≥130 ms + nsIVCD  91/454 9.1 1.84 /1.48-2.29) <0.001 1.74 (1.39-2.17) <0.001 
  QRS ≥130 ms + RBBB  111/524 9.5 1.92 (1.57-2.34) <0.001 1.73 (1.41-2.13) <0.001 
  QRS ≥130 ms + LBBB 318/1789 7.6 1.54 (1.35-1.76) <0.001 1.46 (1.27-1.67) <0.001 
       
Cardiovascular death       
Normal QRS duration (<110 ms) 1028/6506 6.0 1.00 (Ref)  1.00 (Ref)  
QRS 110-129 ms 574/2588 8.7 1.45 (1.31-1.61) <0.001 1.39 (1.25-1.54) <0.001 
QRS ≥130 ms 638/2767 8.4 1.51 (1.36-1.66) <0.001 1.39 (1.26-1.55) <0.001 
  QRS ≥130 ms + nsIVCD  106/454 9.4 1.56 (1.28-1.91) <0.001 1.46 (1.19-1.79) <0.001 
  QRS ≥130 ms + RBBB  126/524 9.7 1.62 (1.35-1.95) <0.001 1.48 (1.23-1.79) <0.001 
  QRS ≥130 ms + LBBB 406/1789 8.8 1.46 (1.30-1.64) <0.001 1.35 (1.19-1.52) <0.001 
       
All-cause mortality       
Normal QRS duration (<110 ms) 1234/6506 7.2 1.00 (Ref)  1.00 (Ref)  
QRS 110-129 ms 667/2588 10.1 1.41 (1.28-1.55) <0.001 1.35 (1.22-1.48) <0.001 
QRS ≥130 ms 740/2767 10.5 1.46 (1.33-1.59) <0.001 1.33 (1.21-1.46) <0.001 
  QRS ≥130 ms + ns IVCD  126/454 11.1 1.55 (1.29-1.86) <0.001 1.45 (1.20-1.76) <0.001 
  QRS ≥130 ms + RBBB  143/524 11.0 1.53 (1.29-1.82) <0.001 1.37 (1.15-1.64) <0.001 
  QRS ≥130 ms + LBBB 471/1789 10.2 1.41 (1.27-1.57) <0.001 1.28 (1.15-1.44) <0.001 
       
Pump failure death       
Normal QRS duration (<110 ms) 192/6506 1.1 1.00 (Ref)  1.00 (Ref)  
QRS 110-129 ms 132/2588 2.0 1.79 (1.44-2.24) <0.001 1.70 (1.36-2.14) <0.001 
QRS ≥130 ms 155/2767 2.2 1.96 (1.59-2.43) <0.001 1.63 (1.30-2.03) <0.001 
  QRS ≥130 ms + ns IVCD  25/454 2.2 1.98 (1.31-3.01) 0.001 1.73 (1.12-2.66) 0.013 
  QRS ≥130 ms + RBBB  38/524 2.9 2.63 (1.85-3.72) <0.001 2.18 (1.53-3.13) <0.001 
  QRS ≥130 ms + LBBB 92/1789 2.0 1.77 (1.38-2.27) <0.001 1.44 (1.11-1.87) 0.006 
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Sudden cardiac death       
Normal QRS duration (<110 ms) 488/6506 2.8 1.00 (Ref)  1.00 (Ref)  
QRS 110-129 ms 260/2588 3.9 1.38 (1.19-1.61) <0.001 1.33 (1.14-1.55) <0.001 
QRS ≥130 ms 281/2767 4.0 1.39 (1.20-1.62) <0.001 1.37 (1.17-1.59) <0.001 
  QRS ≥130 ms + ns IVCD  42/454 3.7 1.30 (0.95-1.78) 0.102 1.24 (0.90-1.71) 0.191 
  QRS ≥130 ms + RBBB  46/524 3.5 1.24 (0.91-1.67) 0.167 1.15 (0.84-1.57) 0.371 










Event rate               





(95% CI) (95% CI) 
       
Any QRS ≥130 ms 1234/7888 6.1     
Baseline QRS <110 ms 511/5691 3.4 1.00 (ref.)  1.00 (ref.)  
Baseline QRS 110-129 ms 723/2197 14.1 4.97 (4.38-5.65) <0.001 4.64 (4.07-5.28) <0.001 
 





    
Baseline QRS <110 ms 264/5691 1.8 1.00 (ref.)  1.00 (ref.)  
Baseline QRS 110-129 ms 285/2197 5.5 3.06 (2.57-3.65) <0.001 2.89 (2.41-3.46) <0.001 
QRS ≥130 ms RBBB 190/7888 0.9     
Baseline QRS <110 ms 75/5691 0.5 1.00 (ref.)  1.00 (ref.)  
Baseline QRS 110-129 ms 115/2197 2.1 4.14 (3.08-5.56) <0.001 3.89 (2.87-5.27) <0.001 
QRS ≥130 ms LBBB 495/7888 2.4     
Baseline QRS <110 ms 172/5691 1.1  1.00 (ref.)  1.00 (ref.)  

















Table 4: Baseline characteristics in patients with QRS <130 ms at baseline according to future QRS -widening in patients with one 


















No. patients 6654 1234  549 190 495  
Age (years) 62 (12) 64 (11) <0.001 61.7 (11.6) 65.5 (11.3) 64.8 (10.4) <0.001 
Female sex 1585 (24%) 237 (19%) <0.001 96 (18%) 32 (17%) 109 (15%) 0.12 
Region 
  North America 
  Latin America 
  Western Europe 
  Central Europe 
































Systolic BP (mmHg) 124 (17) 124 (18) 0.52 124 (18) 124 (19) 124 (17)  0.83 
Heart rate (bpm) 73 (13) 71 (13) <0.001 71 (13) 72 (14) 71 (12) 0.24 
BMI (kg/m2) 28 (6) 28 (5) 0.84 28 (5) 28 (5) 28 (5) 0.17 
eGFR (mL/min/1.73 m2) 72 (59, 85) 71 (59, 85) 0.51 74 (61, 86) 68 (57, 84) 69 (58, 84) 0.006 
Chronic kidney disease* 1713 (26%) 320 (26%) 0.89 122 (22%) 61 (32%) 137 (28%) 0.014 
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Ischaemic HF aetiology 3804 (57%) 740 (60%) 0.068 338 (62%) 126 (66%) 276 (56%) 0.024 
Time since diagnosis of HF 
  <1 year 
  1-5 years 



































KCCQ CSS 80 (63, 92) 80 (65, 92) 0.58 81 (64, 92) 80 (63, 92) 80 (66, 91) 0.94 
NYHA Class 
  I 
  II 
  III 



























Hypertension 4607 (69%) 832 (67%) 0.21 357 (63%) 130 (68%) 355 (72%) 0.013 
Diabetes 2049 (31%) 395 (32%) 0.40 175 (32%) 56 (30%) 164 (33%) 0.65 
Atrial fibrillation (history) 2450 (37%) 388 (31%) <0.001 158 (29%) 74 (39%) 156 (32%) 0.034 
Atrial fibrillation (ECG) 1994 (30%) 292 (24%) <0.001 108 (20%) 59 (31%) 125 (25%) 0.004 
Prior HF hospitalization 3264 (49%) 574 (47%) 0.10 253 (46%) 82 (43%) 239 (48%) 0.47 
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Prior myocardial Infarction 2557 (38%) 547 (44%) <0.001 258 (47%) 100 (53%) 189 (38%) <0.001 
Prior stroke 520 (8%) 81 (7%) 0.13 40 (7%) 11 (6%) 30 (6%) 0.65 
Beta blockers 6180 (93%) 1124 (91%) 0.027 496 (90%) 177 (93%) 451 (91%) 0.50 
MRAs 3072 (46%) 550 (45%) 0.30 243 (44%) 84 (44%) 223 (45%) 0.96 
Diuretics 5184 (78%) 997 (81%) 0.024 434 (79%) 151 (80%) 412 (83%) 0.20 















Table 5 Predictors of incident QRS widening >130ms during follow-up (irrespective of 
morphology 
  
Univariate model  
OR (95% CI) 
P  
Multivariable model 
OR (95% CI) 
P 
QRS 110-129 vs <110 ms 4.97 (4.39-5.65) <0.001 4.55 (3.98-5.19) <0.001 
Age per 5y increase 1.05 (1.02-1.08) <0.001 1.06 (1.03-1.10) 0.001 
Men vs. women 1.32 (1.13-1.53)  1.13 (0.95-1.34 0.155 
HF duration      
1-5 years vs <1 year 1.61 (1.37-1.88) <0.001 1.23 (1.05-1.44) 0.009 
>5 years vs < 1 year 1.28 (1.11-1.48) 0.001 1.29 (1.08-1.54) 0.004 
NYHA III-IV vs. I-II 1.14 (0.99-1.31) 0.067 1.14 (0.98-1.34) 0.091 
LVEF per 1% decrease 1.03 (1.02-1.05) <0.001 1.03 (1.02-1.05) <0.001 
Pulse, per 5 bpm decrease 1.09 (1.06-1.12) <0.001 1.06 (1.02-1.09) <0.001 
SBP per 5 mmHg decrease 0.99 (0.98-1.01) 0.524 0.99 (0.97-1.01) 0.277 
BMI per 1 unit increase 1.00 (0.99-1.01) 0.84 1.01 (0.99-1.02) 0.236 
NT-proBNP per 100 pg/ml 
increase 
1.00 (1.00-1.00) 0.388 1.00 (1.00-1.00) 0.586 
eGFR, per 5 unit increase 0.99 (9,98-1.01) 0.314 1.01 (1.00-1.03) 0.109 
Atrial fibrillation 0.79 (0.69-0.90) <0.001 0.88 (0.75-1.02) 0.093 
Prior MI 1.28 (1.13-1.44) <0.001 1.14 (0.99-1.31) 0.077 
Prior Stroke 0.83 (0.65-1.06) 0.129 0.77 (0.59-1.00) 0.048 
Prior HF hospitalization 0.90 (0.80-1.02) 0.101 0.93 (0.82-1.07) 0.318 


























Any incident QRS≥130ms    
Primary composite    
No incident QRS≥130ms 1453/7888 7.4  1.00 (ref.)  
Any incident 
QRS≥130ms 
196/880 13.9  1.49 (1.25-1.76) <0.001 
All-cause mortality     
No incident QRS≥130ms 905/7888 4.4  1.00 (ref.)  
Any incident 
QRS≥130ms 
170/988 13.0  1.69 (1.43-2.00) <0.001 
    
Incident nsIVCD     
Primary composite     
No incident nsIVCD 1548/7888 7.7 1.00 (ref.)  
Incident ns IVCD 62/373 13.4 1.50 (1.16-1.95) 0.002 
All-cause mortality     
No incident nsIVCD 1004/7888 4.7 1.00 (ref.)  
Incident nsIVCD 71/415 13.7 1.88 (1.47-2.40) <0.001 
    
Incident RBBB    
Primary composite     
No incident RBBB 1585/7888 7.7 1.00 (ref)  
Incident RBBB 25/149 13.3 1.34 (0.90-1.99) 0.15 
All-cause mortality     
No incident RBBB 1047/7888 4.8 1.00 (ref.)  
Incident RBBB 28/168 12.7 1.51 (1.04-2.21) 0.032 
    
Incident LBBB    
Primary composite    
No incident LBBB 1540/7888 7.6   1.00 (ref.)  
Incident LBBB 70/358 14.7    1.42 (1.12-1.82) 0.005 
All-cause mortality     
No incident LBBB 1088/7888 4.7   1.00 (ref.)  

































Figure 3: Cumulative incidence of nsIVCD (A) and incident RBBB (B) incident LBBB (C) and 
















Supplementary Figure 1: Continuous relation between QRS duration and outcomes 
irrespective of morphology. 
 
